Construction of Fusion Protein for Enhanced Small RNA Loading to Extracellular Vesicles

Area of Science:

• Biotechnology and Bioengineering
• Cell Biology
• Gene Therapy

Background:

• Extracellular vesicles (EVs) are natural carriers of RNA and proteins, offering potential as therapeutic delivery vehicles.
• Current methods for loading therapeutic RNAs, like microRNAs (miRNAs), into EVs are inefficient, limiting their clinical application.
• Enhancing RNA loading into EVs is crucial for developing effective EV-based gene therapies.

Purpose of the Study:

• To develop and characterize a novel fusion protein (hCD9.hAGO2) for enhancing small RNA loading into EVs.
• To evaluate the efficiency of RNA transfer and functional effects of engineered EVs in recipient cells.

Main Methods:

• Construction of a fusion protein combining the EV membrane protein CD9 with the RNA-binding protein AGO2 (hCD9.hAGO2).
• Engineering producer cells to express the hCD9.hAGO2 fusion protein.
• Isolation and characterization of engineered EVs and assessment of their RNA cargo and recipient cell effects.

Main Results:

• EVs engineered with hCD9.hAGO2 exhibited significantly higher levels of loaded miRNA and shRNA compared to control EVs.
• hCD9.hAGO2 engineered EVs demonstrated enhanced transfer of RNA cargo to recipient cells.
• Treatment with hCD9.hAGO2 engineered EVs increased the viability of human umbilical vein endothelial cells (HUVECs) without detectable changes in gene expression.

Conclusions:

• The hCD9.hAGO2 fusion protein effectively enhances RNA loading and delivery via engineered EVs.
• Engineered EVs show potential for therapeutic applications, including improving cell viability.
• This study provides a valuable tool for the future development of enhanced EV-based RNA therapeutics.